Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Kamal Mostafa	2. Issuer Name and Ticker or Trading Symbol MAGELLAN HEALTH INC [ MGLN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) CEO, Magellan Rx Management
(Last)          (First)          (Middle) 15950 NORTH 76TH STREET, SUITE 200	3. Date of Earliest Transaction (MM/DD/YYYY) 12/9/2019
(Street) SCOTTSDALE, AZ 85260 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Common Stock, $0.01 par value	12/9/2019		X(1)		16666	A	$60.55	19459	D
Ordinary Common Stock, $0.01 par value	12/9/2019		X(1)		100	A	$64.87	19559	D
Ordinary Common Stock, $0.01 par value	12/9/2019		S(1)		16766	D	$78.7154 (2)	2793	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$60.55	12/9/2019		X (1)			16666	(3)	8/3/2025	Common Stock	16666	$0.00 (4)	0	D
Stock Option (right to buy)	$64.87	12/9/2019		X (1)			100	(3)	3/3/2026	Common Stock	100	$0.00 (4)	7206	D

Explanation of Responses:
(1)	This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
(2)	The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $78.15 to $80.00, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
(3)	All of the stock options in this tranche have vested in full.
(4)	Not applicable.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Kamal Mostafa 15950 NORTH 76TH STREET SUITE 200 SCOTTSDALE, AZ 85260			CEO, Magellan Rx Management

Signatures
/s/ Mostafa Kamal		12/11/2019
**Signature of Reporting Person		Date